GlassScriptPhysician profile
Daniel M Helburn
NPI 1558307025
$1,870.78
in general payments reported to CMS, 2019-2025
21 companies · $656 in 2025
The $656 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $159 · 2021: $91.04 · 2022: $67.17 · 2023: $397 · 2024: $501 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $353.90 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.51 | 2020-2024 | Entyvio |
| Gilead Sciences, INC. | $183.82 | 2020-2025 | |
| Ardelyx, INC. | $176.61 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $144.78 | 2023-2025 | Dupixent |
| Celgene Corporation | $140.75 | 2021-2024 | Zeposia |
| Pfizer INC. | $129.88 | 2024-2025 | |
| Qol Medical, LLC | $78.55 | 2024 | Sucraid |
| Janssen Biotech, INC. | $74.70 | 2022-2025 | Stelara, Tremfya |
| Medtronic, INC. | $69.08 | 2025 | Barrx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.09 | 2020-2023 | Trulance |
| Phathom Pharmaceuticals, INC. | $36.79 | 2023-2024 | Voquezna |
| Fresenius Kabi USA, LLC | $36.16 | 2024 | Idacio |
| Madrigal Pharmaceuticals | $35.56 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $31.90 | 2021-2023 | Ocaliva |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $26.47 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $19.21 | 2024 | |
| Pentax of America, INC. | $17.63 | 2023 | Pentax Medical |
| Vivus LLC | $17.10 | 2025 | Pancreaze |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Helburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.